Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. Yu K, et al. Among authors: yee d. Front Oncol. 2023 Jun 13;13:1192208. doi: 10.3389/fonc.2023.1192208. eCollection 2023. Front Oncol. 2023. PMID: 37384294 Free PMC article.
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP; I-SPY 2 Investigators; Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. Gallagher RI, et al. Among authors: yee d. Cell Rep Med. 2023 Dec 19;4(12):101312. doi: 10.1016/j.xcrm.2023.101312. Epub 2023 Dec 11. Cell Rep Med. 2023. PMID: 38086377 Free PMC article.
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.
Zhang AJ, Ball G, Zundell MP, Agüero R, Yee D, Shields A, Asare C, Navrazhina K, Liu W, Foolad N, Kwock J, Tejwani P, Hamade H, Jaleel T, Butler D, Silverberg N, Nattkemper L, Siegel DM, Tan J, Kim BS, Larocca C, Shinohara MM, Ehlert A, Latella J, Guttman-Yassky E, Krueger JG, Strand V, Armstrong AW, Merola JF, Perez-Chada L, Gottlieb AB. Zhang AJ, et al. Among authors: yee d. J Drugs Dermatol. 2024 Dec 1;23(12):1114-1120. doi: 10.36849/jdd.8363. J Drugs Dermatol. 2024. PMID: 39630678
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Among authors: yee d. Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39625569
839 results